Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the m

Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.

Abstract: The invention relates to a device for adsorbing odours comprising an absorbent layer and an adsorbent layer, said adsorbent layer being provided with a material permeable to volatile organic compounds (VOCs) and an adsorbent particulate filler comprising at least one spice. Such a device is particularly useful for adsorbing and masking body odours.

Abstract: The present invention relates to a plasma reactor and more specifically to an plasma microreactor comprising a support, made at least partially of a dielectric material, the support comprising a gas inlet, a liquid inlet, at least a fluid outlet, a liquid microchannel in the support, a gas channel, at least a ground electrode, at least a high voltage electrode, separated from the gas channel by the dielectric material of the support, wherein said ground electrode and said high voltage electrode are arranged on opposite sides of the gas channel so as to be able to create an electric field inside the gas channel, wherein the liquid microchannel and the gas channel are contiguous and at least an opening is arranged between the liquid microchannel and the gas channel so as to form a fluid channel and to cause the liquid flow contact the gas flow and wherein the liquid flow is retained within the liquid microchannel by capillarity action.

Abstract: A negative electrode active material for a lithium-ion battery has the following formula (I): Li1-xOHFe1+xS (I). x varies from 0.00 to 0.25, preferably from 0.05 to 0.20.

Abstract: The present invention concerns a reactor for the conversion of carbon dioxide or carbon monoxide into hydrocarbon and/or alcohol comprising a support made from an electrically and thermally conductive material, forming the wall or walls of at least one longitudinal channel that passes through the support and also acting as the cathode of the reactor, at least one wire electrode forming an anode of the reactor, and extending within each longitudinal channel, and being arranged at a distance from the wall or walls of the longitudinal channel, each wire electrode optionally being covered with an electrically insulating layer along the part of the wire electrode extending within the longitudinal channel, a catalyst capable of catalysing a conversion reaction for the conversion of carbon dioxide or carbon monoxide into hydrocarbon and/or alcohol, the catalyst being situated between the wire electrode and the wall or walls of each longitudinal channel.

Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the m

Abstract: The invention relates to a process for determining an infiltration profile of biological cells of interest in a biological object of interest from a digital histopathological image of biological tissues, a histological stain having previously been applied to the biological tissues, comprising generating a biological cell detection image, pixels associated with the histological stain on the histopathological image being of a predetermined color on said image, determining a distance map comprising distance iso-curves to the boundary of the biological object, and, from the distance map, calculating a curve representative of the surface density of biological cells of interest as a function of distance to the boundary, by counting, for each boundary distance value, pixels that are both of the predetermined color on the detection image and located between the iso-curve associated with said distance value and the consecutive iso-curve.

Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.

Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.

Abstract: The present invention relates to 4-azapodophyllotoxin analogs of formula (I) in which X, R1, R2, R3, R4 and Ar are as defined in claim 1, preferably a pharmaceutically acceptable salt thereof, optionally in the form of a solvate, a composition comprising said analogs, their use as medicament, in particular for the treatment of cancer, and a process for their preparation.

Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.

Abstract: The present invention relates to 4-azapodophyllotoxin analogs of formula (I) in which X, R1, R2, R3, R4 and Ar are as defined in claim 1, preferably a pharmaceutically acceptable salt thereof, optionally in the form of a solvate, a composition comprising said analogs, their use as medicament, in particular for the treatment of cancer, and a process for their preparation.

Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.